Navamedic Investor Relations Material
Latest events
Q2 2024
Navamedic
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Navamedic
Access all reports
Segment Data
Access more data
Revenue by
Geography
Norway
Sweden
Denmark
Finland
Other
Expenses by
Financials
Navamedic ASA is a Norwegian pharmaceutical company developing, producing, marketing and selling prescription and non-prescription pharmaceuticals, medical nutrition products and medical devices in the Nordic region. The company offers prescription products for use in the treatment of a variety of conditions including: phenylketonuria; homocystinuria; maple syrup urine disease; tyrosinemia, methylmalonic acidemia/propionic acidemia; glutaric aciduria, isovaleric acidemia and urea cycle disorders.
Key slides for Navamedic
Q3 2023
Navamedic
Q4 2023
Navamedic
Latest articles
Qualcomm: Quality Communication and Semiconductor Innovation
Founded in 1985, Qualcomm has transformed the digital communication industry with CDMA technology and its advanced semiconductor business.
13 Sep 2024
Strong Opinions, Loosely Held: Pontus Dackmo on Flexibility and Market Psychology
After a two-decade career in finance, Pontus Dackmo co-founded Protean Funds Scandinavia in 2022, where he now serves as CEO and Investment Manager.
4 Sep 2024
Novo Nordisk: The Danish Pharmaceutical Titan Revolutionizing Global Healthcare
Novo Nordisk's rise to becoming Europe's largest company, reshaping global healthcare and Denmark's economy.
5 Sep 2024
Ticker symbol
NAVA
Country
🇳🇴 Norway